Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1648, Issue 1-2, 2003, Pages 75-83

  Bos, Ineke G A ^a   De Bruin, Eric C ^a   Karuntu, Yani A ^a   Modderman, Piet W ^a   Eldering, Eric ^a   Hack, C Erik ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

C1 Inh; Complement; Inflammation; Kinetics; Recombinant; Serpin

Indexed keywords

ANTIINFLAMMATORY AGENT; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12A; COMPLEMENT COMPONENT C1S INHIBITOR; KALLIKREIN; PROTEIN INHIBITOR; COMPLEMENT C1 INHIBITOR, HUMAN; ISOPROTEIN; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR;

ARTICLE; BLOOD LEVEL; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MONITORING; GLYCOSYLATION; HUMAN; NONHUMAN; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ANALYSIS; THERMOSTABILITY; BIOSYNTHESIS; GENETICS; HEAT; METABOLISM; MOLECULAR CLONING; PICHIA; TRANSGENIC ORGANISM;

PICHIA; PICHIA PASTORIS;

CLONING, MOLECULAR; COMPLEMENT C1 INACTIVATOR PROTEINS; GLYCOSYLATION; HEAT; HUMANS; ORGANISMS, GENETICALLY MODIFIED; PICHIA; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; SERPINS;

EID: 0037968253     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-9639(03)00107-9     Document Type: Article

References (40)

1. Chan J.Y., Burrowes C.E., Habal F.M., Movat H.Z. The inhibition of activated factor XII (Hageman factor) by antithrombin III: the effect of other plasma proteinase inhibitors. Biochem. Biophys. Res. Commun. 74:1977;150-158.
2. Cooper N.R. The classical complement pathway: activation and regulation of the first complement component. Adv. Immunol. 37:1985;151-216.
3. Pixley R.A., Schapira M., Colman R.W. The regulation of human factor XIIa by plasma proteinase inhibitors. J. Biol. Chem. 260:1985;1723-1729.
4. Schapira M., Scott C.F., Colman R.W. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J. Clin. Invest. 69:1982;462-468.
5. Schapira M., de Agostini A., Schifferli J.A., Colman R.W. Biochemistry and pathophysiology of human C1 inhibitor: current issues. Complement. 2:1985;111-126.
6. Sim R.B., Reboul A., Arlaud G.J., Villiers C.L., Colomb M.G. Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma. FEBS Lett. 97:1979;111-115.
7. van der Graaf F., Koedam J.A., Bouma B.N. Inactivation of kallikrein in human plasma. J. Clin. Invest. 71:1983;149-158.
8. Wuillemin W.A., Minnema M., Meijers J.C., Roem D., Eerenberg A.J., Nuijens J.H., ten Cate H., Hack C.E. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood. 85:1995;1517-1526.
9. Caliezi C., Wuillemin W.A., Zeerleder S., Redondo M., Eisele B., Hack C.E. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol. Rev. 52:2000;91-112.
10. Huber R., Carrell R.W. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry. 28:1989;8951-8966.
11. Seo E.J., Lee C., Yu M.H. Concerted regulation of inhibitory activity of alpha 1-antitrypsin by the native strain distributed throughout the molecule. J. Biol. Chem. 277:1902;14216-14220. (2002 Apr.).
12. Stein P.E., Carrell R.W. What do dysfunctional serpins tell us about molecular mobility and disease? Nat. Struct. Biol. 2:1995;96-113.
13. Elliott P.R., Lomas D.A., Carrell R.W., Abrahams J.P. Inhibitory conformation of the reactive loop of alpha 1-antitrypsin. Nat. Struct. Biol. 3:1996;676-681.
14. Loebermann H., Tokuoka R., Deisenhofer J., Huber R. Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J. Mol. Biol. 177:1984;531-557.
15. Eldering E., Nuijens J.H., Hack C.E. Expression of functional human C1 inhibitor in COS cells. J. Biol. Chem. 263:1988;11776-11779.
16. Lamark T., Ingebrigtsen M., Bjornstad C., Melkko T., Mollnes T.E., Nielsen E.W. Expression of active human C1 inhibitor serpin domain in Escherichia coli. Protein Expr. Purif. 22:2001;349-358.
17. Werten M.W., van den Bosch T.J., Wind R.D., Mooibroek H., de Wolf F.A. High-yield secretion of recombinant gelatins by Pichia pastoris. Yeast. 15:1999;1087-1096.
18. Boehm T., Pirie-Shepherd S., Trinh L.B., Shiloach J., Folkman J. Disruption of the KEX1 gene in Pichia pastoris allows expression of full-length murine and human endostatin. Yeast. 15:1999;563-572.
19. Sreekrishna K., Kropp K.E., Wolf K. Nonconventional Yeasts in Biotechnology. A Handbook. 1996;203-253.
20. Vedvick T., Buckholz R.G., Engel M., Urcan M., Kinney J., Provow S., Siegel R.S., Thill G.P. High-level secretion of biologically active aprotinin from the yeast Pichia pastoris. J. Ind. Microbiol. 7:1991;197-201.
21. Bock S.C., Skriver K., Nielsen E., Thogersen H.C., Wiman B., Donaldson V.H., Eddy R.L., Marrinan J., Radziejewska E., Huber R. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry. 25:1986;4292-4301.
22. Carter P.E., Dunbar B., Fothergill J.E. Genomic and cDNA cloning of the human C1 inhibitor. Intron-exon junctions and comparison with other serpins. Eur. J. Biochem. 173:1988;163-169.
23. Nuijens J.H., Huijbregts C.C., van Mierlo G.M., Hack C.E. Inactivation of C-1 inhibitor by proteases: demonstration by a monoclonal antibody of a neodeterminant on inactivated, non-complexed C-1 inhibitor. Immunology. 61:1987;387-389.
24. Nuijens J.H., Eerenberg-Belmer A.J., Huijbregts C.C., Schreuder W.O., Felt-Bersma R.J., Abbink J.J., Thijs L.G., Hack C.E. Proteolytic inactivation of plasma C1-inhibitor in sepsis. J. Clin. Invest. 84:1989;443-450.
25. Nuijens J.H., Huijbregts C.C., Eerenberg-Belmer A.J., Abbink J.J., Strack V.S.R., Felt-Bersma R.J., Thijs L.G., Hack C.E. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. Blood. 72:1988;1841-1848.
26. Bos I.G., van Mierlo G.J., Bleeker W.K., Rigter G.M., te V.H., Dickneite G., Hack C.E. The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model. Int. Immunopharmacol. 1:2001;1583-1595.
27. de Smet B.J., de Boer J.P., Agterberg J., Rigter G., Bleeker W.K., Hack C.E. Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats. Blood. 81:1993;56-61.
28. Cugno M., Bos I., Lubbers Y., Hack C.E., Agostoni A. In vitro interaction of C1-inhibitor with thrombin. Blood Coagul. Fibrinolysis. 12:2001;253-260.
29. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
30. Eldering E., Huijbregts C.C., Lubbers Y.T., Longstaff C., Hack C.E. Characterization of recombinant C1 inhibitor P1 variants. J. Biol. Chem. 267:1992;7013-7020.
31. Morrison J.F., Walsh C.T. The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Areas Mol. Biol. 61:1988;201-301.
32. Aulak K.S., Eldering E., Hack C.E., Lubbers Y.P., Harrison R.A., Mast A., Cicardi M., Davis A.E. A hinge region mutation in C1-inhibitor (Ala436→Thr) results in nonsubstrate-like behavior and in polymerization of the molecule. J. Biol. Chem. 268:1993;18088-18094.
33. Carrell R.W., Owen M.C. Plakalbumin, alpha 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. Nature. 317:1985;730-732.
34. Pemberton P.A., Stein P.E., Pepys M.B., Potter J.M., Carrell R.W. Hormone binding globulins undergo serpin conformational change in inflammation. Nature. 336:1988;257-258.
35. Pemberton P.A., Harrison R.A., Lachmann P.J., Carrell R.W. The structural basis for neutrophil inactivation of C1 inhibitor. Biochem. J. 258:1989;193-198.
36. Trimble R.B., Atkinson P.H., Tschopp J.F., Townsend R.R., Maley F. Structure of oligosaccharides on Saccharomyces SUC2 invertase secreted by the methylotrophic yeast Pichia pastoris. J. Biol. Chem. 266:1991;22807-22817.
37. Duman J.G., Miele R.G., Liang H., Grella D.K., Sim K.L., Castellino F.J., Bretthauer R.K. O-Mannosylation of Pichia pastoris cellular and recombinant proteins. Biotechnol. Appl. Biochem. 28:1998;39-45.
38. Eldering E., Huijbregts C.C., Nuijens J.H., Hack C.E. The balance between inhibition and substrate-type reactions of recombinant C1 inhibitor P5/P3 variants. Behring-Inst.-Mitt. 1993;125-130.
39. Wuillemin W.A., Eldering E., Citarella F., de Ruig C.P., ten Cate H., Hack C.E. Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J. Biol. Chem. 271:1996;12913-12918.
40. Minta J.O. The role of sialic acid in the functional activity and the hepatic clearance of C1-INH. J. Immunol. 126:1981;245-249.